wipo’s patent services for external users
DESCRIPTION
WIPO’s Patent services for external users. Lutz Mailänder Head, Patent Information Section Global IP Infrastructure Sector. Geneva 18 June 2013. Overview. Search reports for developing countries (WPIS) - PowerPoint PPT PresentationTRANSCRIPT
WIPO’s Patent services for external users
Lutz Mailänder
Head, Patent Information Section
Global IP Infrastructure SectorGeneva18 June 2013
Overview
Search reports for developing countries (WPIS)
Search and examination reports for patent offices in developing countries (complementing the PCT; ICE)
Capacity building for examiners in using examination results for members of the patent family
Patent landscapes
Platform for national patent registers
Background information
Links
„I have a PCT application – how can I find out what the status is in country X ?“
Open Innovation platforms: WIPO Green, WIPO Re:Search
WIPO's patent landscape project
Dedicated website
Links to published reports
Links to groups/institutions active in the field
General background/information
Sample of individual report website
Three standard components:
Report body (.PDF)
Database (.xls)
Interactive visualization (Intellixir)
Phase 1 work and collaborations
UNITAID/Medicines Patent Pool (MPP):
Ritonavir (Landon IP)
Atazanavir (Thomson)
WHO: Vaccine manufacturing (FIST)
DNDI: Patents related to 5 neglected diseases
FAO:
Adaptation technologies for improving plant salinity tolerance (PIIPA)
IRENA, GIWEH:
Desalination technologies, and use of renewable energies for desalination (CambridgeIP)
Water purification (CambridgeIP)
(no partner):
Solar cooling (IP Search); Solar cooking (Scope)
Collaborations
Collaboration partners contribute expertise in technical field
WIPO contributes expertise in coordination PLRs and funding
Each collaboration serves as vehicle for partners to familiarize themselves with patent information, analytics, patent system
Collaboration in drafting TOR, delivery phase, evaluation of PLR
WIPO Patent Landscape project
Evaluation after Phase I
Phase II (2012-13)
Budget for 6 further PLRs
Capacity building
Manual for best practices
Regional Workshop for exchange of best practices
Refining standardized tools/procedures of Phase I and developing into future standard service
Ritonavir patent landscape report
Objectives of report:
Identify all patents claiming an invention related to the active ingredient (synthesis, combinations, applications,..)
Analysis of patenting activity
Identify sample innovation tracks, subsequent generations of patents claiming subsequent improvements, new inventions (“evergreening”)
Detailed description of search methodology for pharmaceuticals; suitable as training example
Ritonavir patent landscape report
823 patent families claiming Ritonavir related inventions according to claim language
Many more potentially relevant IP rights in comparison to Orange book of US FDA
To be taken into account in case of technology transfer, local production, procurement through generics: licensing key patent is not enough
Average 13.4 patents per INPADOC family
Largest patenting activity in combination therapies (400 families)
4 sample innovation tracks (liquid and solid dosage forms, synthesis, structural aspects and polymorphs)
1 additional innovation track
Backward citation analysis only revealed patents claiming analogs
Interactive Visualization
Database of Ritonavir related patents
Publication number linked to Espacenet; sortable
Technology categories; sortable
Innovation tracks
Sometimes key inventions take place,
e.g. pharmaceutical substances
Trigger series of further developments
e.g. combinations/formulations, synthesis,....
Starting point of subsequent generations of related patents protecting the further innovation
Such later patents perpetuate protection beyond the 20 years after the filing of the initial patent
I.e. certain technologies using the initial invention may still be protected though protection of first invention may have expired
Orange book: US patents on Ritonavir
Indentification of innovation tracks
Categorizing of patents during retrieval stage
Indentifying most active assignees in particular category
Reviewing documents citing the key patent
Citation map analysis to identify "citation tracks" by exploring backward and forward citations
Claim (granted) analysis to identify
overlap of claim, e.g. confirm similar scope of protection
New aspects of later generation (additional file inspection (via US PAIR))
Key patent:
Markush formula
2nd generation
1st liquid dosage
no 3rd generation
2nd generation
Combination
Potentially liquid3rd generation
Liquid dosage3d generation
Potentially liquid
4th generation
Liquid dosage
5th generation
Capsule for lq. Dos.
5th generation
More specific liquid dosage
Innovation tracks explored
Innovation tracks were selected with a view to relevance for generic production in DCs
In initial report:
Liquid oral dosage forms
Synthesis of Ritonavir and key intermediates
Structural considerations and polymorphs
Solid dosage forms
Following later request from DNDI:
Prodrugs of Ritonavir
Search methodology
Report includes extensive description of name search strategies
Names of pharmaceuticals change over phases of drug development
E.g. "Atazanavir", the non proprietary generic name, was assigned at later clinical stage by WHO in 2001 (priority year of founder patent 1995)
Various pre-clinical names
Various chemical naming conventions
CAS registry code CAS-198904313-31-3
Alternatively to Orange Book, founder family can be found by searching for SPCs in INPADOC using Atazanavir since SPC are granted at later stage when generic name is known
3rd alternative to identify founder patent is backward citation analyis.
Naming history
Clinical names (usually language independent):
Manufacturer name:
CGP-73547, CGP-73355, CGP-75136, BM-75136
Generic name (USAN naming protocol), International Nonproprietary Name (INN):
Atazanavir
Also used for bioequivalents
Brand name (product):
Rayataz
Clinical names in AB,TI,CL + descriptionAbsence of red in neighborhood of yellow indicates potential noise
Clinical names in AB,TI,CL,DEcleaned collection
Additional DE are not shown as dots;
TI/AB/CL are more evenly spread
Atazanavir filing activity per dvlpm stage
Commercial versus public sector filings
Atazanavir – categories of technologies
Individual documents may be placed in multiple categories
Created by automated clustering using natural language processing
Collaboration between Novartis and BMS
Atazanavir – citation map
Atazanavir – citation map
Atazanavir – citation map
PLR on vaccines
Two parts of PLR
Part 1: Vaccine related patents in general
Part 2: Vaccines for selected diseases (Pneumonia)
Special focus on Brazil, India, China
Vaccines: total filings
Vaccines: origin of PCT applications
Vaccines:OFF
Vaccines: China
Vaccines: China top applicants
Vaccines: top applicants
